GNH India 3 Expanded Access Program (EAP) Execution Capabilities A strategic execution partner for specialty pharmaceutical access programs in India, supporting innovators in delivering orphan, rare, and critical therapies through compliant, patient-centric pathways.
WHO WE ARE Specialty Pharma Access Partner GNH India Pharmaceuticals Limited Established specialty pharmaceutical access and supply partner with deep expertise in navigating complex regulatory and distribution pathways in the Indian market. Orphan & Rare Disease Focus Dedicated focus on orphan, rare, and critical therapies where patient access is time- sensitive and regulatory pathways require specialized expertise and compliant execution. Pre-Approval Access Experience Proven track record supporting pre-approval and early access pathways, enabling patients to receive life-saving therapies before formal commercial launch while maintaining full regulatory compliance. Compliance-First Philosophy Operations guided by a compliance-first, patient-centric philosophy that prioritizes ethical access, regulatory adherence, and alignment with innovator medical governance frameworks.
EXPANDED ACCESS PROGRAMS EAP / Named Patient Program Focus Program Execution Model GNH India provides comprehensive execution support for Expanded Access Programs (EAPs) and Named Patient Programs, operating within physician- initiated, non-promotional supply models that maintain clear separation from commercial distribution activities. Our approach ensures full alignment with innovator medical and regulatory governance frameworks, supporting ethical access while protecting the integrity of future commercialization strategies. Every program is designed with compliance at the forefront, adhering to local regulations and international best practices. We serve as the critical bridge between innovator companies and patients in need, managing the operational complexity of early access while innovators maintain complete control over medical oversight, patient eligibility criteria, and program parameters. Physician-Initiated Supply Non-promotional models supporting legitimate medical need Governance Alignment Full integration with innovator medical and regulatory controls Commercial Separation Clear boundaries protecting future commercial pathways
CORE CAPABILITIES Execution Capabilities GNH India delivers comprehensive, end-to-end operational support for expanded access programs, managing every aspect of the execution chain with precision and regulatory rigor. Our capabilities span the entire patient journey, from initial regulatory coordination through final product delivery and ongoing documentation.
- Local Regulatory Coordination Expert navigation of Indian regulatory requirements, including DCGI coordination, import licensing, and documentation management for compassionate use and named patient access pathways.
- Importation & Logistics Management Comprehensive import coordination, customs clearance, and logistics management including cold-chain handling for temperature-sensitive biologics and specialty pharmaceuticals requiring controlled storage conditions.
- End-to-End Case Management Dedicated case management support from initial request through product delivery, including patient eligibility verification, physician coordination, and real-time program tracking and reporting.
- Audit-Ready Documentation Comprehensive documentation and traceability systems maintaining complete chain-of-custody records, regulatory filings, and audit trails meeting international compliance standards and innovator quality requirements.
MARKET POSITION Geographic & Operational Strength
- India Execution Base Strong operational infrastructure and regulatory expertise within the Indian market, with established relationships across regulatory bodies, healthcare institutions, and logistics networks.
- Global Innovator Experience Proven track record working with multinational pharmaceutical innovators, understanding the governance requirements and operational standards expected by global organizations.
- Innovator-Defined Controls Operational flexibility to work within innovator-defined standard operating procedures, quality systems, and control frameworks, ensuring seamless integration with existing governance structures.
- Scalable Model Execution model designed to scale from individual named patient cases to broader expanded access programs without creating conflicts or complications for future commercial launch strategies.
PARTNERSHIP MODEL How We Partner GNH India operates as a local execution partner only, with innovator companies retaining complete control over all clinical, medical, and strategic aspects of expanded access programs. This clear delineation ensures program integrity while enabling efficient local execution. Innovator Retains Full Control Patient Eligibility Criteria Innovators define and control all patient eligibility requirements, inclusion and exclusion criteria, and approval processes for program participation. Medical Oversight Complete medical governance remains with the innovator, including safety monitoring protocols, adverse event reporting, and clinical decision-making authority. Program Scope & Duration Innovators maintain full authority over program parameters, geographic scope, enrollment caps, treatment duration limits, and program continuation or discontinuation decisions. GNH India's Role Local Execution Partner GNH acts exclusively as the local execution partner, managing operational implementation while innovators maintain strategic and medical control. Our execution-focused partnership model is specifically designed to support ethical access ahead of regulatory approval, providing patients with life-saving therapies while protecting the innovator's future commercial strategy and maintaining the highest standards of regulatory compliance. This structure ensures clear accountability, streamlined operations, and alignment with both local regulatory requirements and international pharmaceutical governance standards. Execution partner for regulated early access 4 not a commercial distributor.